HARBIN, China, May 5 /PRNewswire-Asia/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company was recently elected as a Deputy Chair of Heilongjiang Medical Association ("the Association") by members of the Association.
Established in 2006, the Association is an industry-supported, non-profit organization with over 130 member institutions, including pharmaceutical companies, other healthcare firms and scientific research organizations. Its purpose is to promote the advancement of medical research and support the development of healthcare-related industries in Heilongjiang province. The Association plays an important role in facilitating communication between members and other relevant institutions, such as Heilongjiang's Food and Drug Administration, apprising members of industry trends and guiding members on technological advancements and other innovations. The Association also assists the local and provincial government in evaluating important scientific and technological projects and setting relevant policies. As a Deputy Chair of the Association, Renhuang will play a leading role in guiding the organization's development, helping to shape the future of Heilongjiang's healthcare industry and influence the industry's working relationship with the local and regional government.
"We are honored to be elected as the Deputy Chair Unit of the Association and support its mission to develop Heilongjiang's pharmaceutical industry," said Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "We believe Renhuang's election is a recognition of the Company's leadership in the pharmaceutical industry and, as the Deputy Chair Unit, look forward to the opportunity to shape the discussions and decisions related to the strategic development of Heilongjiang's pharmaceutical industry."
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, visit http://www.renhuang.com .
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's role as Deputy Chairman Unit of Heilongjiang Medical Association, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
Company Contact:
Renhuang Pharmaceuticals, Inc.
Ms. Portia Tan, IR Contact
Tel: +86-451-5392-5461
Email: ir@renhuang.com
CCG Investor Relations:
Ms. Lei Huang, Account Manager
Tel: +1-646-833-3417 (New York)
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
